Generic Name: osimertinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: AstraZeneca

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A


Drug Indication

Tagrisso is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time or who have experienced disease progression on a different EGFR inhibitor.


General Info

Tagrisso interferes with epidermal growth factor receptor (EGFR) proteins that play a role in cancer cell growth and development of blood vessels that feed tumors. Certain EGFR mutations promote lung tumor growth and metastasis.

The FLAURA trial, which enrolled previously untreated people with metastatic NSCLC with specific EGFR exon 19 or 21 mutations, showed that Tagrisso delayed disease progression and improved overall survival more than chemotherapy. The AURA3 study showed that Tagrisso also shrank tumors and delayed progression more than chemotherapy in patients who had received prior treatment including other EGFR inhibitors. Tagrisso was first approved in 2015.


Dosage

Dosing Info:

Tagrisso is a once-daily pill that can be taken with or without food.


Side Effects

Common side effects include diarrhea, rash, dry skin, nail problems, fatigue and decreased appetite. Potential serious side effects may include lung and heart problems and inflammation of the corneas of the eyes. Tagrisso can cause fetal harm if used during pregnancy.


For More Info: https://www.tagrisso.com

Patient Assistance Program Info: https://www.tagrisso.com/support/register.html

Last Reviewed: October 23, 2019